TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Confo Therapeutics
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia

Confo Therapeutics has selected CFTX-2034, an SSTR5 agonist antibody, as a development candidate to treat Post-Bariatric Hypoglycemia (PBH). The antibody aims to restore balanced insulin response and address hypoglycemic episodes after weight loss surgery.

Insights
SMMNY   neutral

Recognized as a significant market participant in medical imaging technologies


LLY   neutral

Mentioned as a previous collaborator who out-licensed CFTX-1554 in 2023, with no direct impact in this article